Results 181 to 190 of about 201,985 (355)

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Is there the phenotype of chronic heart failure with “intermediate” left ventricular ejection fraction? Additional echocardiographic criteria for left ventricular systolic dysfunction in patients with chronic heart failure of ischemic origin with ejection fraction in the “gray area”

, 2021
В. В. Сыволап, В. А. Лысенко   +1 more
openalex   +2 more sources

Association between Left Ventricular Systolic Dysfunction and Mortality in Patients with Septic Shock [PDF]

, 2020
Sua Kim, Jung-Dong Lee, Beong Ki Kim, Yong‐Hyun Kim, Je Hyeong Kim   +4 more
openalex   +1 more source

Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats

ESC Heart Failure, Volume 12, Issue 2, Page 1304-1315, April 2025.
Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction
Einar Sjaastad Nordén, Bård Andre Bendiksen, Kaja Knudsen Bergo, Emil Knut Stenersen Espe, Gary McGinley, Almira Hasic, Ida Marie Hauge‐Iversen, Hege Katrin Ugland, Xin Shen, Michael Frisk, Nishani S. Mabotuwana, William E. Louch, Rizwan I. Hussain, Lili Zhang, Ivar Sjaastad, Alessandro Cataliotti, Geir Christensen   +16 more
wiley   +1 more source

The place of Indapamide retard in the treatment of patients with left ventricular dysfunction and preserved systolic function in the presence of arterial hypertension

, 2013
С. Н. Терещенко, И. В. Жиров   +1 more
openalex   +1 more source

Left Cardiac Ventricular Systolic Dysfunction Evaluation [PDF]

, 2020
openaire   +1 more source

Left atrial function in uraemic patients: Four‐dimensional automatic left atrial quantitative technology study

ESC Heart Failure, Volume 12, Issue 2, Page 1316-1325, April 2025.
Abstract Objective This study aimed to evaluate the utility of left atrial volume and function in uraemic patients using four‐dimensional automatic left atrial quantification (4D auto LAQ) technology. Methods Thirty‐four undialysed uraemic patients (U‐ND group), 60 dialysed uraemic patients (U‐D group), and 32 healthy volunteers (N group) were enrolled
Bing Li, Meihua Chen, Xuning Huang
wiley   +1 more source

Understanding longitudinal bi-ventricular structural and functional changes in a Pulmonary Hypertension Sugen-Hypoxia rat model by Cardiac Magnetic Resonance Imaging [PDF]

, 2020
Buist, Hanna, Church, A. Colin, Gallagher, Lindsay, Holmes, William M., Hughes, Colin, Jayasekera, Geeshath, Johnson, Martin K., MacLean, Mandy R., Mullin, James, Nilsen, Margaret, Peacock, Andrew J., Uckan, Aysel, Welsh, David J., Wilson, Kathryn S., Woodward, Rosemary   +14 more
core   +2 more sources

Importance of Treadmill Exercise Time as an Initial Prognostic Screening Tool in Patients With Systolic Left Ventricular Dysfunction [PDF]

, 2009
Eileen Hsich, Eiran Z. Gorodeski, Randall C. Starling, Eugene H. Blackstone, Hemant Ishwaran, Michael S. Lauer   +5 more
openalex   +1 more source